Treosulfan for Conditioning in Children and Adolescents Before Hematopoietic Stem Cell Transplantation (HSCT)  by Peters, Christina et al.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S150eS166S164conditioning regimen consisted of Cyclophosphamide with
either total body irradiation or Busulfan, with the addition of
Fludarabine in 13 patients (62%). In vivo T cell depletion with
Anti-Thymocyte Globulin was performed in 18 patients
(85%), and 11 donor grafts underwent ex vivo T cell depletion
(52%). Donor source included HLA-matched sibling (n¼3),
mismatched related donor (n¼1), unrelated marrow (n¼12)
and unrelated cord blood (n¼5). 58% of unrelated donors had
at least 1 HLA mismatch. Neutrophil engraftment for the
entire cohort was 90%, and 100% for those patients that
received Fludarabine. The incidence of acute GVHD was 19%
for the entire cohort. 5 year Overall Survival (OS) was 32%,
with a relapse rate of 20% (Figure). Of the patients that
received Fludarabine, 5 year OS was 38% with a relapse rate
of 30%. For the patients with biallelic BRCA2 mutation, 5 year
OS was 33% with a relapse rate of 50%
Our study provides evidence for use of HCT with a Flu-
darabine containing regimen for FA patients with acute
leukemia or advanced MDS, who would otherwise have
a dismal prognosis. The role of pre-HCT chemotherapy
remains unclear, and requires further investigation. BRCA2
patients are a unique subset of FA patients and require
tailored therapy to optimize HCT outcomes.
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To identify possible dose related toxicities of treosulfan
containing regimen and determine the incidence of
engraftment, treatment related mortality (TRM), overall
survival (OS) and event free survival (EFS) we explored 616
patients (pts) below 18 years who underwent HSCT between
January 2005 and July 2010 for malignant (n¼ 270, 43%) ornon malignant disease (n ¼ 356, 57%). To investigate
a potential non-linear association between dose and
outcome, fractional polynomials were used.533 pts under-
went allogeneic, 93 autologous HSCT. 513 (83%) pts received
a treosulfan-based conditioning regimen during their ﬁrst
HSCT. 124 (20%) had a matched sibling donor (MSD). The
stem cell source was bone marrow (BM) in 274 pts (44%) and
peripheral blood in 264 pts (42%).In the group of pts with
allogeneic HSCT, 41 were below the age of 6 months and 65
between 6-months and 1 year. 314 were between 1 and 12
years and 101 above 12 years. For allogeneic HSCT, the
median treosulfan dose was 42 g/msq (12-46). 24 pts (5%)
received less then 33 g/msq. 153 pts (29%) received between
33 and 39 g/msq. The majority of pts received a treosulfan
dose between 39 and 45 g/msq.
Results: There is no signiﬁcant correlation of the time to ANC
> 0.5x10e9/L with age and treosulfan-dose. Primary graft
failure occurred in 2% of cases with no signiﬁcant correlation
with age, treosulfan dose and underlying disease in uni- and
multivariate analysis. Acute graft-versus-host disease
(GvHD) of grade III-IV occurred in 10% of the patients and the
rate of limited and extended chronic GvHD was 13% and 6%,
respectively. The most common grade 3 or 4 toxicities were
diarrhoea (24%), stomatitis (22%), and SGOT elevation (25%).
Veno-occlusive disease was described in 5% of all pts. There
was a signiﬁcant association between age and VOD-inci-
dence, with higher VOD-rates in children below the age of
0.5 years (12%), that are exclusively children with non-
malignant diseases. Treosulfan-dose has no signiﬁcant
impact on VOD and GVHD in both univariate and multivar-
iate analysis. There is a border-line signiﬁcant impact of age
on overall survival. The 3-years pOS in children below 6
months, between 6 months and 1 year between 1-12 years
and > 12 years is 75%, 84%, 70% and 60%, respectively. This
difference is mainly caused by a difference in disease related
mortality (DRM). TRM is not signiﬁcantly different in the
different age groups. With respect to dose, we did not ﬁnd
a signiﬁcant impact on overall survival, neither in univariate
nor in adjusted analysis. However, therewas a better OS after
ﬁrst HSCT (0,74%) compared to second or third HSCT (0,51%),
P < .001.
Conclusion: These results emphasise the low toxicity proﬁle
of treosulfan, even in heavily pre-treated children and
adolescents and in patients undergoing a second HSCT. It was
shown that treosulfan is highly efﬁcient to enable engraft-
ment without increasing the risk for severe acute or chronic
GVHD.100
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Background: Myeloablative conditioning with busulfan and
cyclophosphamide (200 mg/kg) (Bu/CY) followed by HLA-
